

ENCORIUM GROUP INC  
Form 3  
November 09, 2006

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Å Manninen Petri Mikael		(Month/Day/Year)	ENCORIUM GROUP INC [ENCO]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
		11/01/2006		
VANILJAKUJA 6			(Check all applicable)	
(Street)			<input checked="" type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
HELSINKI, Å H9 Å 00990			<input type="checkbox"/> Officer	<input type="checkbox"/> Other
(City)	(State)	(Zip)	(give title below)	(specify below)
				6. Individual or Joint/Group Filing(Check Applicable Line)
				<input checked="" type="checkbox"/> Form filed by One Reporting Person
				<input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock \$0.001 per share	232,814	I	By a Corporation <u>(1)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	

Edgar Filing: ENCORIUM GROUP INC - Form 3

			Shares	(I) (Instr. 5)			
Stock Option (Right to Buy) <sup>(2)</sup>	11/01/2006	01/31/2009	Common Stock \$0.001 per share	50,630 <sup>(3)</sup>	\$ 2.31 <sup>(4)</sup>	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Manninen Petri Mikael VANILJAKUJA 6 HELSINKI, H9 00990	Â X	Â	Â	Â

## Signatures

/s/ Petri Mikael  
Manninen  
11/08/2006

\*\*Signature of Reporting Person                      Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person is managing director of NTGLT Pharma BVBA which owns 232,814 shares of Encorium Group, Inc.  
The business combination between Encorium Group Inc. ("Encorium") and Remedium Oy, a Finnish corporation, closed on Nov. 1, 2006. All options to purchase shares of Remedium stock, including a Remedium option held by the reporting person, remained intact.
- (2) Upon exercise, however, the Remedium option will automatically entitle the option holder to receive, and the option currently represents the right to receive, shares of Encorium Common Stock in lieu of Remedium stock.  
Represents the maximum number of Encorium shares subject to the stock option. The actual number of Encorium shares purchasable under the stock option may be less, depending on post-closing adjustments (if any) under the terms of the business combination between Encorium and Remedium.
- (3) The reporting person holds a stock option to purchase 120 Remedium shares at 750 Euros per share, which currently represents the right to purchase a maximum of 50,630 shares of Encorium Common Stock. As a result, each Remedium share subject to the option represents the right to buy a maximum of 422 Encorium shares at 1.78 Euros per shares (approximately \$2.31 per share, depending on the exchange rate). If the actual number of shares purchasable under the option will be less than 50,630 shares, the exercise price will be higher.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.